2022. Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s66. DOI:https://doi.org/10.25251/skin.6.supp.66.